Supprelin-LA, is an under the skin implant formulated by using Histrelin Acetate, produced by Indevus Pharmaceuticals Inc., is the 50mg dose as formally approved by the United States Food and Drugs Administration – FDA. Supprelin-LA has been directed for the treatment of Central Precocious Puberty – CPP which is the premature beginning of teens or youth in the children. Through the unique technique known as Hydron Implant, developed by Indevus Pharmaceuticals Inc, Supprelin-LA is usually inserted under the skin just once every year in the inner side of upper arm and is typically designed to provide consistent discharge of nearly 65 mcg per day through 12 months of the gonadotropin releasing hormone–GnRH analog Histrelin.

Central Precocious Puberty-CPP is significant and consistently known condition which may have intense physical and psychological repercussions on the children as well as their families. Supprelin-LA would prove to be the remarkable medication therapy in treating the CPP by providing the faster and continual suppression of hormone levels for the complete one year after taking a single dose. Supprelin-LA is the only product that provides the treatment plan comprising of singular dosing episode once every year as compared to the other therapies that direct taking injections every three weeks or four weeks at the most.

Supprelin-LA also offers the patients and their families the quicker and lasting treatment alternative that remarkably minimizes the inconvenience of frequent dosing and enhance continual fulfillment. There are no remarkable serious side effects exhibited by Supprelin-LA except the one most commonly reported adverse reaction may be the reaction at the implant site.